argenx Q1 Sales Soar 63% to $1.3B, Key PDUFA Decision Nears for VYVGART Expansion
ARGX sits 58% above its 52-week low of $510.055.
Summary
argenx reported robust first quarter 2026 global product net sales of $1.3 billion, marking a substantial 63% year-over-year increase. The company also provided a significant business update, including a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026, for the anti-AChR antibody negative gMG label expansion. Additionally, positive topline results from the ADAPT OCULUS study were presented, supporting a planned sBLA submission for ocular MG. This strong financial performance and pipeline progress follow the recent appointment of Karen Massey as CEO. The impressive sales growth for VYVGART underscores strong commercial execution, while the imminent PDUFA decision and positive trial data represent critical near-term catalysts that could significantly expand VYVGART's market reach. Traders should monitor the FDA decision on May 10 and upcoming trial readouts for myositis and MMN later this year.
At the time of this announcement, ARGX was trading at $807.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.1B. The 52-week trading range was $510.06 to $934.62. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.